Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DCBY02 in Advanced or Metastatic Solid Tumors
NCT05496595Phase 1Terminated
- Sponsor
- DynamiCure Biotech
- Start
- Oct 2022
- Primary completion
- Feb 2024
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label trial of DCBY02 in solid tumor (advanced stage), metastatic solid tumors, colorectal cancer (CRC) and 9 more (2 arms), sponsored by DynamiCure Biotech. Primary endpoints: Incidence of Dose-Limiting Toxicities at 28 days and Frequency and Severity of Treatment-Emergent Adverse Events at 28 days. Started Oct 2022; status: terminated.
02
Drugs
DCBY02
03
Conditions
solid tumor (advanced stage)metastatic solid tumorscolorectal cancer (CRC)gastric cancer (GC)non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT05496595.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05496595.